Patents Assigned to Bristol-Myers Squibb
  • Ternary ligand complexes useful as radiopharmaceuticals
    Patent number: 6403054
    Abstract: The present invention provides novel radiopharmaceuticals useful for imaging the heart, brain, lungs, liver or kidneys, kits useful for preparing the radiopharmaceuticals, and methods of imaging the heart, brain, lungs, liver or kidneys in a patient in need of such imaging. The radiopharmaceuticals are comprised of technetium or rhenium radionuclide complexes of a ternary ligand system: one hydrazido or diazenido ligand, one aminoalcohol ligand, and one pi-acid ligand selected from phosphines, arsines, and imine nitrogen-containing heterocycles. The radiopharmaceuticals have the formula, ML1L2L3, wherein the variables are as defined herein.
    Type: Grant
    Filed: May 28, 1997
    Date of Patent: June 11, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Shuang Liu
  • KCNQ potassium channels and methods of modulating same
    Patent number: 6403360
    Abstract: The present invention relates to KCNQ proteins defining potassium channels. In particular, the invention concerns the human KCNQ2, human KCNQ3, murine KCNQ2, and rat KCNQ2 proteins reported herein. KCNQ2 and KCNQ3 proteins are nervous system-selective and may be involved in neurotransmission and neuroprotection. The KCNQ2 and KCNQ3 of the present invention can be used to assay for modulators of the proteins, which would be useful in treatment of such disorders as ataxia, myokymia, seizures, Alzheimer's disease, Parkinson's disease, age-associated memory loss, learning deficiencies, motor neuron diseases, epilepsy, stroke, and the like.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: June 11, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Blanar, Paul C. Levesque, Wayne A. Little, Michael G. Neubauer, Wen-Pin Yang
  • Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
    Patent number: 6399773
    Abstract: The present invention discloses the identification of the novel inhibitors of IMPDH (inosine-5′-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH mediated diseases, such as transplant rejection and autoimmune diseases.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: June 4, 2002
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Chunjian Liu, T. G. Murali Dhar, Henry H. Gu, Edwin J. Iwanowicz, Katerina Leftheris, William J. Pitts
  • 12,13-modified epothilone derivatives
    Patent number: 6399638
    Abstract: The present invention relates to 12,13-position modified epothilone derivatives, methods of preparation of the derivatives and intermediates therefor.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: June 4, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Gerhard Höfle
  • Process for the preparation of &agr;' chloroketones
    Patent number: 6399793
    Abstract: The present invention relates to a process for the preparation of &agr;′ chloroketones, such as 4-phenyl-3-t-butyloxy-carbonylamino)-2-keto-1-chlorobutane by reacting certain aryl amino acid esters, e.g. N-(2-t-butoxycarbonyl)-L-phenylalanine-4-nitrophenyl ester, with a sulfur ylide compound to form the corresponding keto ylide compound which is then treated with a source of chloride and an organic acid.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: June 4, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Kronenthal, Mark D. Schwinden
  • Therapeutic usage of tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
    Patent number: 6399609
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I: and their use in treating anxiety, depression, and other psychiatric and neurological disorders.
    Type: Grant
    Filed: May 11, 2000
    Date of Patent: June 4, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Richard Gerald Wilde
  • Efficient method for the conversion of nitriles to amidines
    Patent number: 6399784
    Abstract: The present invention relates to processes for the conversion of nitrites to amidines in the preparation of compounds which are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex. The compounds described herein are potent thrombolytics and useful for the inhibition of platelet aggregation in the treatment of thromboembolic disorders.
    Type: Grant
    Filed: January 10, 2001
    Date of Patent: June 4, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Philip Ma, Pasquale N. Confalone, Hui-Yin Li
  • Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
    Patent number: 6395767
    Abstract: Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R1, R2, R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor *or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: May 28, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, Richard B. Sulsky, David J. Augeri, David R. Magnin, Lawrence G. Hamann, David A. Betebenner
  • Benzamide ligands for the thyroid receptor
    Patent number: 6395784
    Abstract: New thyroid receptor ligands are provided which have the general formula in which: X is —O—, —S—, —CH2—, —CO—, or —NH—; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R2 and R3 being other than hydrogen; R4 is methyl, ethyl, n-propyl or trifluoromethyl; R5 is hydrogen or lower alkyl; R6 is carboxylic acid, or esters or prodrugs; R7 is hydrogen or an alkanoyl or an aroyl. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: May 28, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventor: Denis E. Ryono
  • Thiourea derivatives of dihydropyridine NPY antagonists
    Patent number: 6391881
    Abstract: A series of antagonists of NPY have been synthesized and are comprised of thiourea linked piperazine and piperidine derivatives of 4-phenyl-1,4-dihydropyridines of Formula 1. where Z is NR7R8 or and X is CH or N. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: May 21, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventor: Sing-Yuen Sit
  • Process for preparing arylacetylaminothiazoles
    Patent number: 6392053
    Abstract: The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazole compounds of formula I or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R4, R5, R6, R8, R9, R12 and R13 are each independently hydrogen, alkyl, aryl or heteroaryl; R3, R7, R10 and R11 are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; and X is CH or N, which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention also concerns a new process for the preparation of formylarylacetates and formylarylacetic acids.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: May 21, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bang-Chi Chen, Kyoung S. Kim, S. David Kimball, Raj N. Misra, Joseph E. Sundeen, Rulin Zhao
  • System for control of blood processor
    Patent number: 6393369
    Abstract: A blood processor is provided with a computer and memory, and external to the blood processor there is provided a general purpose computer system programmed with a convenient interface for creating scripts; the general purpose computer system translates the scripts into custom interpretive code adapted for processing by the computer in the blood processor, and the code is written into the memory of the blood processor via the computer in the blood processor.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: May 21, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventor: Raymond A. Carr
  • Radioactive seeds for brachytherapy and a process for making the same
    Patent number: 6391279
    Abstract: Novel radioactive seeds for brachytherapy and a reproducible method of manufacturing the seeds is described, wherein the seeds contain either Pd-103 or I-125 disposed within a cured resin matrix.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: May 21, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Prahlad R. Singh, Gerald P. Tercho, Jack N. Wentz, Keith R. Olewine
  • Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors
    Patent number: 6391919
    Abstract: This invention relates generally to bis-amino acid sulfonamides containing substituted benzyl amines of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as HIV protease inhibitors, pharmaceutical compositions and diagnostic kits comprising the same, methods of using the same for treating viral infection or as assay standards or reagents, and intermediates and processes for making the same.
    Type: Grant
    Filed: January 12, 2000
    Date of Patent: May 21, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Robert F. Kaltenbach, George L. Trainor
  • Inhibitors of farnesyl protein transferase
    Patent number: 6387926
    Abstract: Disclosed are quinoline and benzazepine derivatives that inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogenic protein Ras. Thus, the compounds are useful as anti-cancer agents. The compounds are also useful in the treatment of diseases other than cancer.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: May 14, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Charles Z. Ding, John T. Hunt, Soong-Hoon Kim, Katerina Leftheris
  • Apparatus and methods for preparing plasma solutions from blood with improved separation of plasma
    Patent number: 6387263
    Abstract: An improved plasma separation device and method involve the use of a retaining means with a centrifugal plasma separation device for retaining unwanted blood components, e.g., lipids or lipoproteins, from passing from a separation chamber in the device to a collection chamber in the device along with the separated plasma.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: May 14, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gautam Bhaskar, Glenn A. Joergensen
  • Oxidation hair dyeing systems and process for providing more equalized coloration on new and old growth hair
    Patent number: 6379399
    Abstract: Oxidative hair dyeing systems are provided that are “root seeking”, i.e., which produce more intense initial coloration on new growth, less porous hair compared to the initial coloration produced in older, damaged, more porous hair. More equalized coloration along the shaft of hair can be obtained with the “root seeking” dyeing products.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: April 30, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gottfried Wenke, Michael Y. M. Wong
  • Benzoazepines and analogs thereof useful as growth hormone secretagogues
    Patent number: 6380184
    Abstract: Benzoazepines of the following formula wherein R1, R1a, R2, R9k, L, Q, X, Y and Z are as described herein, and analogs thereof are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: April 30, 2002
    Assignee: Bristol-Myers Squibb Co.
    Inventor: James J. Li
  • 12, 13-cyclopropane epothilone derivatives
    Patent number: 6380395
    Abstract: The present invention relates to 12,13-position modified epothilone derivatives, methods of preparation of the derivatives and intermediates therefor.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: April 30, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Gerhard Höfle
  • Inhibiting B cell activation with soluble CD40 or fusion proteins thereof
    Patent number: 6376459
    Abstract: The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40/immunoglobulin fusion protein or antibody specific for gp39 on T cells was able to inhibit helper T-cell mediated B-cell activation by binding to a novel 39 kD protein receptor on helper T-cell membranes. The present invention provides for a substantially purified CD40CR receptor; for soluble ligands of CD40CR, including antibodies as well as fusion molecules comprising at least a portion of CD40 protein; and for methods of controlling B-cell activation which may be especially useful in the treatment of allergy or autoimmune disease, including graft-versus-host disease and rheumatoid arthritis.
    Type: Grant
    Filed: August 31, 1993
    Date of Patent: April 23, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alejandro A. Aruffo, Jeffrey A. Ledbetter, Ivan Stamenkovic, Randolph Noelle